203 related articles for article (PubMed ID: 24167104)
21. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
22. Assessing neuropathic pain in patients with low back-related leg pain: Comparing the painDETECT Questionnaire with the 2016 NeuPSIG grading system.
Hasvik E; Haugen AJ; Gjerstad J; Grøvle L
Eur J Pain; 2018 Jul; 22(6):1160-1169. PubMed ID: 29436056
[TBL] [Abstract][Full Text] [Related]
23. Beliefs about hydroxyurea in youth with sickle cell disease.
Badawy SM; Thompson AA; Liem RI
Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):142-148. PubMed ID: 29397333
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.
Adewoyin AS; Oghuvwu OS; Awodu OA
Afr Health Sci; 2017 Mar; 17(1):255-261. PubMed ID: 29026400
[TBL] [Abstract][Full Text] [Related]
25. Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease.
Badawy SM; Barrera L; Cai S; Thompson AA
Biomed Res Int; 2018; 2018():8296139. PubMed ID: 30105252
[TBL] [Abstract][Full Text] [Related]
26. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
Nwenyi E; Leafman J; Mathieson K; Ezeobah N
Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
Rees AL
J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of the painDETECT screening questionnaire for detection of neuropathic components in hospital-based patients with orofacial pain: a prospective cohort study.
Jafree DJ; Zakrzewska JM; Bhatia S; Venda Nova C
J Headache Pain; 2018 Nov; 19(1):103. PubMed ID: 30400770
[TBL] [Abstract][Full Text] [Related]
29. Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.
Han J; Bhat S; Gowhari M; Gordeuk VR; Saraf SL
Pharmacotherapy; 2016 Nov; 36(11):1166-1172. PubMed ID: 27639254
[TBL] [Abstract][Full Text] [Related]
30. Management of Sickle Cell Pain Using Pregabalin: A Pilot Study.
Schlaeger JM; Molokie RE; Yao Y; Suarez ML; Golembiewski J; Wilkie DJ; Votta-Velis G
Pain Manag Nurs; 2017 Dec; 18(6):391-400. PubMed ID: 28843636
[TBL] [Abstract][Full Text] [Related]
31. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
[TBL] [Abstract][Full Text] [Related]
32. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease.
Badawy SM; Thompson AA; Holl JL; Penedo FJ; Liem RI
Pediatr Hematol Oncol; 2018; 35(5-6):297-308. PubMed ID: 30636474
[TBL] [Abstract][Full Text] [Related]
33. Sensory and Thermal Quantitative Testing in Children With Sickle Cell Disease.
Jacob E; Chan VW; Hodge C; Zeltzer L; Zurakowski D; Sethna NF
J Pediatr Hematol Oncol; 2015 Apr; 37(3):185-9. PubMed ID: 25014619
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine B; Neonato MG; Girot R; Aractingi S
Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
[TBL] [Abstract][Full Text] [Related]
35. Only half of the chronic pain after thoracic surgery shows a neuropathic component.
Steegers MA; Snik DM; Verhagen AF; van der Drift MA; Wilder-Smith OH
J Pain; 2008 Oct; 9(10):955-61. PubMed ID: 18632308
[TBL] [Abstract][Full Text] [Related]
36. Patients with sickle cell disease have increased sensitivity to cold and heat.
Brandow AM; Stucky CL; Hillery CA; Hoffmann RG; Panepinto JA
Am J Hematol; 2013 Jan; 88(1):37-43. PubMed ID: 23115062
[TBL] [Abstract][Full Text] [Related]
37. Sickle Cell Disease and Pain: Is it all Vaso-occlusive Crises?
Ramsay Z; Bartlett R; Ali A; Grant J; Gordon-Strachan G; Asnani M
Clin J Pain; 2021 Aug; 37(8):583-590. PubMed ID: 34008506
[TBL] [Abstract][Full Text] [Related]
38. Classifying patients with lumbar spinal stenosis using painDETECT: a cross-sectional study.
Takahashi N; Shirado O; Kobayashi K; Mashiko R; Konno S
BMC Fam Pract; 2016 Jul; 17():90. PubMed ID: 27443164
[TBL] [Abstract][Full Text] [Related]
39. Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis.
Choi JH; Lee SH; Kim HR; Lee KA
Clin Rheumatol; 2018 Nov; 37(11):3077-3086. PubMed ID: 29713968
[TBL] [Abstract][Full Text] [Related]
40. Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease.
Dampier C; Barry V; Gross HE; Lui Y; Thornburg CD; DeWalt DA; Reeve BB
Pediatr Blood Cancer; 2016 Jun; 63(6):1031-7. PubMed ID: 26895143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
